Abstracts

Rationale: Understanding the diverse impact of anti-seizure medications (ASMs) i.e. mono-, bi-, and polytherapy in epilepsy management is crucial for improving patient outcomes. This study aims to evaluate the impact of these ASM regimens on reducing seizure frequency and enhancing quality of life (QOL) in patients with epilepsy (PWE). By analyzing treatment responses and QOL outcomes, our study seeks to provide insights that can inform personalized treatment decisions, ultimately aiming to optimize epilepsy management and improve the overall wel-being of PWE.

Methods: A cross-sectional observational study was conducted, enrolling individuals aged 18 to 65 years with epilepsy. Participants were categorized as responders or non-responders based on the effectiveness of ASM treatment, specifically in reducing seizure frequency over the past year. Descriptive analysis was performed on demographic and clinical data, including seizure frequency, type, age at onset, and details of ASM usage. QOL was assessed using the Quality of Life in Epilepsy Inventory-31 (QOLIE-31).


Results: A total of 100 patients with epilepsy were recruited and included in the study based on the inclusion and exclusion criteria. The median age did not significantly differ between responder and non-responder groups. However, Non-responders groups were observed as a significantly larger proportion (72.1%) compared to responders (27.9%). While monotherapy was more common among responders (48.12%) than polytherapy (22.28%), the distribution differed in non-responders, with a more balanced utilization of monotherapy (29.60%) and polytherapy (52.36%). Despite similar durations of epilepsy, non-responders groups exhibited significantly higher average seizure frequencies. QOL assessments revealed that 38% of individuals were responders, while 62% were non-responders. Overall QOL scores were significantly higher (p < 0.001) in the responders group.